Sarepta Therapeutics, Inc. (SRPT) Rating Reiterated by Oppenheimer Holdings, Inc.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)‘s stock had its “buy” rating reiterated by investment analysts at Oppenheimer Holdings, Inc. in a research report issued to clients and investors on Monday. They currently have a $76.00 price target on the biotechnology company’s stock. Oppenheimer Holdings, Inc.’s target price would suggest a potential upside of 46.95% from the stock’s current price.

Several other research analysts also recently commented on SRPT. SunTrust Banks, Inc. reissued a “buy” rating on shares of Sarepta Therapeutics in a research note on Thursday, July 20th. Credit Suisse Group set a $64.00 price objective on Sarepta Therapeutics and gave the company a “buy” rating in a research note on Tuesday, July 18th. Leerink Swann reissued a “buy” rating and issued a $60.00 price objective (up from $52.00) on shares of Sarepta Therapeutics in a research note on Tuesday, July 18th. BidaskClub raised Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Finally, Royal Bank Of Canada reissued a “buy” rating and issued a $60.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, June 22nd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. Sarepta Therapeutics presently has an average rating of “Buy” and an average target price of $64.34.

Shares of Sarepta Therapeutics (SRPT) opened at 51.72 on Monday. The company has a 50-day moving average of $45.98 and a 200 day moving average of $37.19. Sarepta Therapeutics has a 12 month low of $26.26 and a 12 month high of $55.02. The company’s market cap is $3.33 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.46. The business had revenue of $35.01 million for the quarter, compared to analysts’ expectations of $22.52 million. During the same quarter last year, the business earned ($1.19) EPS. The company’s quarterly revenue was up 350000.0% on a year-over-year basis. On average, analysts anticipate that Sarepta Therapeutics will post ($1.16) earnings per share for the current year.

WARNING: “Sarepta Therapeutics, Inc. (SRPT) Rating Reiterated by Oppenheimer Holdings, Inc.” was first reported by Markets Daily and is the property of of Markets Daily. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.themarketsdaily.com/2017/10/18/sarepta-therapeutics-inc-srpt-rating-reiterated-by-oppenheimer-holdings-inc.html.

In related news, SVP Alexander Cumbo sold 5,918 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $41.00, for a total transaction of $242,638.00. Following the completion of the sale, the senior vice president now directly owns 22,793 shares of the company’s stock, valued at approximately $934,513. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Shamim Ruff sold 12,138 shares of the firm’s stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $42.97, for a total value of $521,569.86. Following the sale, the senior vice president now directly owns 27,312 shares of the company’s stock, valued at $1,173,596.64. The disclosure for this sale can be found here. Insiders have sold a total of 89,556 shares of company stock valued at $3,799,208 over the last three months. Corporate insiders own 9.60% of the company’s stock.

Large investors have recently modified their holdings of the stock. Prentiss Smith & Co. Inc. increased its position in shares of Sarepta Therapeutics by 772.2% during the 2nd quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 3,166 shares during the last quarter. Ameritas Investment Partners Inc. acquired a new stake in shares of Sarepta Therapeutics during the 1st quarter worth about $127,000. Cubist Systematic Strategies LLC increased its position in shares of Sarepta Therapeutics by 116.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 2,474 shares during the last quarter. PNC Financial Services Group Inc. increased its position in shares of Sarepta Therapeutics by 150.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 2,800 shares during the last quarter. Finally, Edge Wealth Management LLC acquired a new stake in shares of Sarepta Therapeutics during the 2nd quarter worth about $175,000. 65.41% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply